Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Aug 04, 2022 10:17am

155 Views

Post# 34870892

RE:DO YOU NOT YET UNDERSTAND WHAT FARRELL HAS DONE?

In all fairness some Penny Stock plays start off with a sound basis for hope that one day the product or business will find strength and succede .

However as time goes on and the process to production drags on and money burns away, companies like CLAS switch to survival mode.

Money has been made by a few but the corporation begins to fail and "Investors" get burned , especially Retail without inside information.

What I'm saying is that most Junior companies start out in good faith with intentions of being successful.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario